Core Viewpoint - The article discusses the controversy surrounding the drug Ergotamine, labeled as a "fake drug" by a prominent figure, which has led to significant public discourse and market reactions related to the company Kolun Pharmaceutical [1] Company Response - Kolun Pharmaceutical's securities department stated that they have not paid attention to the content of the mentioned article and prefer not to comment on others' opinions, emphasizing that investors should make their own judgments based on comprehensive information [1] Market Reaction - Following the controversial promotion of Ergotamine by Kolun Pharmaceutical's chairman, who appeared in a provocative advertisement, there was a notable surge in the stock prices of anti-aging concept stocks in the A-share market [1]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in its net value and returns over various time frames [1] - As of June 3, 2025, the latest net value of the fund is 1.6391 yuan, with a growth of 0.96%. The fund's return over the past month is 7.34%, ranking 224 out of 4690 in its category. Over the past three months, the return is 7.88%, ranking 461 out of 4620, and since the beginning of the year, the return is 8.66%, ranking 977 out of 4568 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management Company in October 2014 [2]

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical industry, specifically recommending an "Accumulate" rating for both the pharmaceutical manufacturing and pharmaceutical services sectors [1][2]. Core Insights - Continuous attention is suggested on innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug industry is experiencing a high demand for assets, with multinational corporations showing greater interest than concerns over geopolitical risks [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Monthly Portfolio Performance - The report highlights a monthly portfolio for June 2025, including companies such as Jiangsu Heng Rui Medicine, Huadong Medicine, and Sichuan Kelun Pharmaceutical, among others [5][36]. - In May 2025, the portfolio achieved an average increase of 7.7%, outperforming the overall pharmaceutical index, which rose by 4.5% [11][37]. Market Performance - In May 2025, the pharmaceutical sector ranked first in performance, with notable sub-sectors like chemical raw materials (+10.5%) and chemical preparations (+9.6%) showing strong growth [20][37]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. International Market Comparison - The Hong Kong pharmaceutical sector outperformed the market with a rise of 7.8%, while the U.S. pharmaceutical sector underperformed, declining by 5.7% [38]. - The report identifies top-performing stocks in both markets, with significant gains in the Hong Kong sector and notable declines in the U.S. sector [38].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].

Group 1 - The Shanghai Composite Index opened lower but rose throughout the day, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7971.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 5.53% in the past month, 7.39% in the past three months, and 7.09% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.29%), WuXi AppTec (16.43%), Pian Zai Huang (6.37%), Yunnan Baiyao (5.21%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (4.06%), Xinhecheng (3.51%), Changchun High-tech (3.48%), Fosun Pharma (3.34%), and Shanghai Raas (3.27%) [1] - The market segments of the CSI 300 Pharmaceutical and Biotechnology Index show that the Shanghai Stock Exchange accounts for 63.65% and the Shenzhen Stock Exchange accounts for 36.35% [2] - The industry composition of the CSI 300 Pharmaceutical and Biotechnology Index includes: chemical drugs (43.80%), pharmaceutical and biotechnology services (21.66%), traditional Chinese medicine (18.52%), and biological drugs (16.02%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index samples [2]

Group 1 - The domestic "Viagra" (Sildenafil Citrate) is facing severe market stagnation, with companies like Baiyunshan and Kelun Pharmaceutical experiencing declining sales and increasing inventory [1][3][4] - A total of 91 different Sildenafil-based drugs have been approved in China, leading to intense price competition, with products like Qilu's "Qianwei" priced as low as 2.08 yuan per tablet [1][6][9] - A survey from Peking University and Fudan University indicates that only 50% of the post-95 generation engage in sexual activity weekly, contributing to the decline in demand for erectile dysfunction medications [1][13] Group 2 - The market for domestic "Viagra" is undergoing unprecedented challenges due to intensified competition, changing consumer perceptions, and societal trends [3][14] - Baiyunshan reported a significant drop in sales of its "Jin Ge" product, with daily sales decreasing by 36,000 tablets compared to the previous year, leading to a nearly 50% increase in inventory [4][5] - Other companies, such as Kelun Pharmaceutical and Tainkang, have also reported substantial declines in revenue and net profit, with Kelun's revenue dropping by 29.42% year-on-year in Q1 2025 [5][6][14] Group 3 - The surge in competing products has led to a "white-hot" market competition, with Baiyunshan attributing its inventory issues to the increasing number of competitors [6][9] - The aggressive pricing strategies of competitors, such as Qilu's "Qianwei," have significantly impacted the market share of established products like "Jin Ge" and even the original brand Viagra [9][11] - Changing health perceptions among consumers, with a shift towards non-drug methods for improving health, is further reshaping the market landscape [13][14]

Core Insights - The 2025 American Society of Clinical Oncology (ASCO) annual meeting will take place in Chicago, showcasing cutting-edge clinical oncology research and treatment outcomes, with significant participation from Chinese companies [1][2]. Group 1: Participation and Research Highlights - Chinese researchers have submitted over 70 original studies for oral presentations, surpassing last year's 55 studies, indicating a growing contribution to global oncology research [2]. - Companies like Dizal Pharmaceutical and China National Pharmaceutical Group will present their latest research on innovative therapies, including PD-1 monoclonal antibodies and antibody-drug conjugates (ADCs) [1][3]. Group 2: Specific Company Developments - Dizal Pharmaceutical will present two innovative products, DZD8586 and DZD6008, focusing on B-cell non-Hodgkin lymphoma and non-small cell lung cancer (NSCLC), with DZD8586 showing an objective response rate (ORR) of 84.2% in heavily pre-treated CLL/SLL patients [3]. - China National Pharmaceutical Group will unveil preliminary data from the first-in-human phase I clinical study of TQB2102, an HER2 bispecific antibody-drug conjugate, reporting an ORR of 51.3% in HER2-positive breast cancer patients [4]. Group 3: Focus on Lung Cancer - Lung cancer remains the leading cause of cancer incidence and mortality, with NSCLC accounting for 80%-85% of cases, prompting multiple companies to target this area for research [5]. - Kelun Pharmaceutical will present six clinical studies, including results for sac-TMT in advanced EGFR-mutant NSCLC, demonstrating significant efficacy compared to docetaxel [5][6]. - Dizal's DZD6008 has shown promising results in a phase I/II study for advanced NSCLC, with an 83.3% tumor reduction rate among previously treated patients [7]. Group 4: Innovation and Market Trends - As of December 31, 2024, China leads globally with 3,575 active innovative drug candidates, and the proportion of domestically approved innovative drugs has increased from under 10% in 2015 to 42% in 2024 [8]. - Large multinational pharmaceutical companies have increasingly sought to acquire Chinese innovative drug candidates, with 31% of new drug candidates sourced from China in 2024, up from 0% in 2019 [8].

Core Viewpoint - The article discusses the performance and holdings of the ICBC Frontier Medical Stock C fund, highlighting its recent growth and ranking among similar funds [1]. Fund Performance - The latest net value of ICBC Frontier Medical Stock C is 2.9850 yuan, reflecting a growth of 3.36% [1]. - The fund's return over the past month is 5.06%, ranking 72 out of 1022 similar funds [1]. - Over the last three months, the return is 10.06%, with a ranking of 63 out of 1009 [1]. - Year-to-date, the fund has achieved a return of 12.46%, ranking 107 out of 999 [1]. Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05% of the fund, with the following key positions: - Heng Rui Medicine: 10.11% - Kelun Pharmaceutical: 8.01% - WuXi AppTec: 7.72% - BeiGene: 6.85% - Xinlitai: 4.90% - Zai Lab: 4.77% - Yuyue Medical: 4.60% - New Horizon: 4.36% - East China Pharmaceutical: 4.20% - Haizhi Pharmaceutical: 3.53% [1]. Fund Background - ICBC Frontier Medical Stock C was established on November 23, 2020, and as of March 31, 2025, it has a total scale of 1.38 billion yuan [1]. - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2].

Group 1 - The pharmaceutical sector in A-shares has experienced a prolonged bear market lasting over three years, with the Shenwan Pharmaceutical and Biological Index declining by 54% during this period [1] - Approximately two-thirds of the existing 600 pharmaceutical funds have a net value below 1 as of May 28, 2023, with the lowest at 0.35 [1] - However, more than half of the pharmaceutical funds achieved positive returns in 2025, with top performers yielding between 47% and 56% [1][2] Group 2 - The core factors driving the recovery of pharmaceutical funds include marginal improvements in the pharmaceutical sector's performance, despite ongoing revenue and profit declines [2][5] - The pharmaceutical sector's revenue is projected to decrease by 0.5% in 2024, with net profit expected to drop by 11% [2] - The overall performance of the pharmaceutical sector showed signs of stabilization in Q1 2025, with a revenue decline of 3.4% and a net profit decrease of 4% [2][5] Group 3 - The pharmaceutical sector's valuation has reached historical lows, making it attractive for investors, with a price-to-earnings ratio of 29x at the beginning of the year [5] - The Shenwan Pharmaceutical and Biological Index has increased by 3.76% from the beginning of the year to May 28, 2023, with notable fluctuations in its performance [6][8] - The recovery in the pharmaceutical sector is driven by investor expectations of stabilization, supported by the release of quarterly reports [8] Group 4 - Innovative drugs are currently the main source of alpha in the pharmaceutical sector, with top-performing funds achieving returns exceeding 40% through active stock selection [9][12] - The top holdings of the Zhongyin Great Health A fund include several leading innovative pharmaceutical companies, all of which saw significant price increases in Q1 2025 [10][12] - The long-term investment strategy of the Zhongyin Great Health A fund focuses on domestic innovative drugs, despite the sector's previous downturn [12] Group 5 - The pharmaceutical sector is expected to benefit from favorable policies supporting innovation, with the domestic innovative drug market entering a harvest phase [18] - The chemical pharmaceutical sub-sector has outperformed due to the market entry of innovative drugs and favorable policy expectations [14][17] - The performance of various pharmaceutical sub-sectors has shown significant differentiation, with innovative drugs presenting clearer investment opportunities [17][19]